
|Articles|August 1, 2003
Radiotherapy for subfoveal CNV has early, but not durable benefits
Author(s)Cheryl Guttman
Fort Lauderdale, FL-High-dose (5 3 4-Gy fractions; 6 MeV) external-beam radiation therapy has only a modest and very short-lived benefit in the treatment of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), according to an interim analysis of data from the Age-Related Macular Degeneration Radiotherapy Trial (AMDRT).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
From bench to bedside: Evolving realities of gene therapy for inherited retinal diseases
2
8 things to know about aflibercept 8 mg for retinal vascular disease
3
Topical liposomal ozonated oil may be a useful treatment in neurotrophic keratopathy
4
Screening for Demodex blepharitis: Integrating best practices into routine eye care
5







































